diagnost tool
higher frequenc higher order fewer death
posit deal rais pt buy
updat model first time bake contribut rep
busi follow surpris announc
announc late august landmark co-promot deal think
deal consist go strategi deal
without execut risk believ well posit expand busi
rais revenu estim bake collabor goe
effect reiter buy rate rais pt
use multipl rais rev
ytd line peer remain one top pick
rais revenu estim rais revenu
y/i
alreadi demonstr sale forc call
doc offic frequent volum grow faster seen thing
compani space notabl think increment
growth come higher reorder exist clinician initi follow
acceler new doc add pace model new doc add
rise new doc add final see modest benefit slightli
cologuard reorder everi year incremental/year time
like even upsid model exclud increment benefit order
american age recommend screen ac
high-risk american colon cancer anoth peopl all-in would
total american time colon cancer test beyond
cologuard think liver test launch american
elig screen never screen thu
earli day penetr goal penetr time
bump revenu rais rev y/i
y/i expect detail clinician among
factor believ well posit achiev guid
given small lift new doc detail addit
reason highlight page note
rais higher market spend rais expens
reflect exass increment market promot
 spend rais out-year expens reflect share portion
 expens deal agre match dollar dollar exass
share expens
bump profit meaning view expect
aggress drive demand forese futur
continu invest busi manag busi high growth go
sever year sinc path gm strong oper
leverag near-term profit time less import view given
bump profit estim one quarter
price close busi septemb
commerci cologuard fda-
screen test detect cancer pre-cancer
polyp develop liquid biopsi test
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
larg health system win key driver next year consid larg
health system one biggest opportun cologuard growth next
year primari care physician employ affili
larg health system cologuard present under-penetrated face
challeng barrier adopt larg health system given diplomat often
complex process establish standard care cancer monitor treatment
howev believ strong tie larg health system help
break ice ramp penetr top us health system
make chang standard care cancer monitoring/treat larg
hospit system often time number key member senior committe
head qualiti head gi head intern medicin etc must consult
indic recent investor confer usual take month schedul
meet variou key committe member six month chang intern
guidelin cancer monitor anoth six month integr cologuard
system happen overnight one year aim drive
adopt larg health system grow dedic system team current
rep prior sale forc expans howev big opportun
leverag much larger team togeth target top
target impli view inflect exist clinician order driven increas
frequenc doc call expand sale forc well addit order
clinician new cologuard pay monthli promot fee equal
increment lab servic revenu exass baselin minimum multipli
gm initi baselin lab revenu target follow
baselin target
also initi baselin target rais
revenu
like deal without risk posit
agreement manag commit long-term success said know
high multipl stock time stock level
requir excel execut opinion near term risk includ
possibl near-term disrupt sale forc focu given start pfizer
collabor ie know much overlap exist exist
rep territori rep know number rep
deploy sell cologuard cologuard priorit pfizer rep product
product hope product cologuard dx learn
curv therapeut rep assum sale forc rep
minimum details/year requir agreement rep would
respons details/year details/day assum work day
calendar year math conduct linkedin search pfizer intern
medicin sale filter profession current employ
return result medium long-term risk includ
success collabor pharma compani awar one
diagnost compani may termin agreement detail
fewer clinician calendar year believ manag like
includ buffer near-term disrupt volum guid q/q note
stock declin volum miss
believ agreement increment help cologuard patient
rescreen everi year unclear exact number rep
co-promot cologuard estim combin sale forc
given expand sale reach increas frequenc call physician
believ adequ engin drive patient rescreen elig
patient last cologuard test rais cologuard patient reorder
rate assum patient popul
elig reorder cologuard
canaccord growth confer boston august manag
indic individu expect screen cologuard
midpoint fy guid elig repeat test
impli increment revenu get elig patient test
buy unchang target price septemb
diagnost tool
test call indic base
elig repeat test year think good
tam number use figur cologuard user could possibl reorder
see driver help enabl hit achiev midpoint volum
revenu guidanc
remov languag letter send cologuard patient
inform possibl risk out-of-pocket cost today almost patient
cover cologuard out-of-pocket expens remark shift year
ago clear languag fairli recent remov think help
complet test
lift newli cover live other
lift newli contract in-network health plan fewer test denial
lift new sale rep combin hire earlier year
new rep messag cologuard patient out-of-pocket cost
increas cologuard reorder elig peopl rescreen
got test cologuard three year ago
lift return kit old order patient worri might get bill
lift focu high-potenti physician
lift focu larger health system
higher percentag electron test order today littl cologuard
order clinician via electron mean think time increas
time data show clinician order electron tend
order test order via fax machin
nation sale meet partial off-set normal
season step order primarili result summer holiday
season impact holiday around thanksgiv christma
possibl modest impact expect detail clinician
agre new collabor agreement plan
develop annual ad market plan later octob realist
contribut volum revenu small mind
given time requir train expect materi posit impact
may
buy unchang target price septemb
diagnost tool
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
buy unchang target price septemb
diagnost tool
buy unchang target price septemb
diagnost tool
author analyst canaccord genuiti whose name appear front page research herebi certifi
recommend opinion express research accur reflect author analyst person independ
object view design invest relev issuer discuss herein within author
analyst coverag univers ii part author analyst compens directli indirectli relat
specif recommend view express author analyst research
analyst employ outsid us regist research analyst finra analyst may associ person
canaccord genuiti llc therefor may subject finra rule nyse rule restrict commun
subject compani public appear trade secur held research analyst account
individu identifi sector coverag cover subject compani industri identifi jurisdict author
analyst report
date time first dissemin septemb et
date time product septemb et
price target use multipl revenu estim million discount back year
price target appli multipl adj ep estim y/i
risk achiev target price valuat
risk model includ number new physician add per quarter physician re-ord rate level
 spend cologuard re-ord year first cologuard user due re-screen
pama pama establish medicar price base weight median commerci payor rate pama present
expect go effect januari though time could push opinion view risk
small none given view pama rate like remain similar present medicar rate
competit mani compani develop colorect screen modal particularli blood test liquid biopsi
compani includ grail name three test like fobt fecal occult blood test
fecal immunochem test use year mani new test offer cancer detect uncertain competit
develop test proven pre-canc claim
reimburs pursu health plan coverag privat commerci payor assur health plan
elect cover cologuard uncertainti price might reimburs test
note typic medic technolog risk risk includ commerci execut sale market team regulatori risk
fda potenti product recal patent infring product liabil lawsuit anti-trust litig
commerci execut season ebb flow involv direct sell primari care physician gi
assur abl meet exceed guidanc provid quarter-to-quart
valuat trade continu trade meaning premium us healthcar compani compani
 result guarante continu trade higher even abl exceed guidanc
util anim health underli demand anim health patient offic visit strong steadi year idexx
could see pressur event underli anim health util reach peak level turn could impli difficult
econom pressur unemploy rate tick lower rel level seen great recess variou
macroeconom headwind could reduc demand diagnost pet servic econom weak could caus pet owner skip
defer visit vet hospit could affect owner willing approv certain diagnost test compli treatment plan
even continu own pet
larg intern exposur deriv revenu outsid north america intern growth rate
commonli exceed unit state guarante occur futur believ intern growth
buy unchang target price septemb
diagnost tool
volatil growth rate us addit currenc fluctuat intern sale may continu
advers impact revenu earn
competit competit veterinari diagnost market high time intens although vet diagnost market
less duopoli compani compet commerci clinic lab hospit clinic lab manufactur multi-test blood
analyz on-sit test system expect competit abaxi particular remain rel high
regulatori risk product subject usda foreign regulatori agenc respect product
approv manufactur market promot label record keep test qualiti storag product dispos howev
regulatori risk lower human medic compani
distribut rate
global stock rate
total includ stock review
buy stock expect gener risk-adjust return next month
hold stock expect gener risk-adjust return next month
sell stock expect gener neg risk-adjust return next month
rate canaccord genuiti provid research coverag relev issuer
risk-adjust return refer expect return relat amount risk associ design invest
specul stock bear significantli higher risk typic valu normal fundament criteria invest
stock may result materi loss
recommend histori date global stock rate tabl
list recommend issuer coverag dissemin preced period
may obtain follow websit provid hyperlink report read electron http //disclosures-
requir company-specif disclosur date public
